Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years

Masatoshi Akiyama; Shingo Takahara; Satoshi Kawatsu; Yoichi Endo; Junko Fujiwara; Osamu Adachi; Kiichiro Kumagai; Shunsuke Kawamoto; Yoshikatsu Saiki

doi:10.1007/s11748-017-0763-3

Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years

Masatoshi Akiyama, Shingo Takahara, Satoshi Kawatsu, Yoichi Endo, Junko Fujiwara, Osamu Adachi, Kiichiro Kumagai, Shunsuke Kawamoto, Yoshikatsu Saiki

Research output: Contribution to journal › Article › peer-review

Abstract

Due to donor shortage, patients with refractory heart failure need to be supported on mechanical circulatory support (MCS). Critically, patients undergo several deployments of MCS in stages inevitably requiring blood products transfusion. MCSs per se along with blood products can trigger immune allosensitization. Antibody-mediated rejection (AMR) is associated with significant mortality after heart transplantation. Here, we present the case with high panel-reactive antibody over 95% who developed AMR early after heart transplantation. This life-threatening complication was successfully treated with multi-modal treatment including anti-CD20 antibody, rituximab.

Original language	English
Pages (from-to)	710-712
Number of pages	3
Journal	General thoracic and cardiovascular surgery
Volume	65
Issue number	12
DOIs	https://doi.org/10.1007/s11748-017-0763-3
Publication status	Published - 2017 Dec 1

Keywords

Antibody-mediated rejection
Heart transplantation
Left ventricular assist device
Panel-reactive antibody
Rituximab

ASJC Scopus subject areas

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11748-017-0763-3

Cite this

Akiyama, M., Takahara, S., Kawatsu, S., Endo, Y., Fujiwara, J., Adachi, O., Kumagai, K., Kawamoto, S., & Saiki, Y. (2017). Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years. General thoracic and cardiovascular surgery, 65(12), 710-712. https://doi.org/10.1007/s11748-017-0763-3

Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years. / Akiyama, Masatoshi; Takahara, Shingo; Kawatsu, Satoshi et al.

In: General thoracic and cardiovascular surgery, Vol. 65, No. 12, 01.12.2017, p. 710-712.

Research output: Contribution to journal › Article › peer-review

Akiyama, M, Takahara, S, Kawatsu, S, Endo, Y, Fujiwara, J, Adachi, O, Kumagai, K, Kawamoto, S & Saiki, Y 2017, 'Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years', General thoracic and cardiovascular surgery, vol. 65, no. 12, pp. 710-712. https://doi.org/10.1007/s11748-017-0763-3

@article{ab08149badc444cba589438d10373377,

title = "Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years",

abstract = "Due to donor shortage, patients with refractory heart failure need to be supported on mechanical circulatory support (MCS). Critically, patients undergo several deployments of MCS in stages inevitably requiring blood products transfusion. MCSs per se along with blood products can trigger immune allosensitization. Antibody-mediated rejection (AMR) is associated with significant mortality after heart transplantation. Here, we present the case with high panel-reactive antibody over 95% who developed AMR early after heart transplantation. This life-threatening complication was successfully treated with multi-modal treatment including anti-CD20 antibody, rituximab.",

keywords = "Antibody-mediated rejection, Heart transplantation, Left ventricular assist device, Panel-reactive antibody, Rituximab",

author = "Masatoshi Akiyama and Shingo Takahara and Satoshi Kawatsu and Yoichi Endo and Junko Fujiwara and Osamu Adachi and Kiichiro Kumagai and Shunsuke Kawamoto and Yoshikatsu Saiki",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s11748-017-0763-3",

language = "English",

volume = "65",

pages = "710--712",

journal = "General Thoracic and Cardiovascular Surgery",

issn = "1863-6705",

publisher = "Springer Japan",

number = "12",

}

TY - JOUR

T1 - Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years

AU - Akiyama, Masatoshi

AU - Takahara, Shingo

AU - Kawatsu, Satoshi

AU - Endo, Yoichi

AU - Fujiwara, Junko

AU - Adachi, Osamu

AU - Kumagai, Kiichiro

AU - Kawamoto, Shunsuke

AU - Saiki, Yoshikatsu

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Due to donor shortage, patients with refractory heart failure need to be supported on mechanical circulatory support (MCS). Critically, patients undergo several deployments of MCS in stages inevitably requiring blood products transfusion. MCSs per se along with blood products can trigger immune allosensitization. Antibody-mediated rejection (AMR) is associated with significant mortality after heart transplantation. Here, we present the case with high panel-reactive antibody over 95% who developed AMR early after heart transplantation. This life-threatening complication was successfully treated with multi-modal treatment including anti-CD20 antibody, rituximab.

AB - Due to donor shortage, patients with refractory heart failure need to be supported on mechanical circulatory support (MCS). Critically, patients undergo several deployments of MCS in stages inevitably requiring blood products transfusion. MCSs per se along with blood products can trigger immune allosensitization. Antibody-mediated rejection (AMR) is associated with significant mortality after heart transplantation. Here, we present the case with high panel-reactive antibody over 95% who developed AMR early after heart transplantation. This life-threatening complication was successfully treated with multi-modal treatment including anti-CD20 antibody, rituximab.

KW - Antibody-mediated rejection

KW - Heart transplantation

KW - Left ventricular assist device

KW - Panel-reactive antibody

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85014056394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014056394&partnerID=8YFLogxK

U2 - 10.1007/s11748-017-0763-3

DO - 10.1007/s11748-017-0763-3

M3 - Article

C2 - 28243893

AN - SCOPUS:85014056394

SN - 1863-6705

VL - 65

SP - 710

EP - 712

JO - General Thoracic and Cardiovascular Surgery

JF - General Thoracic and Cardiovascular Surgery

IS - 12

ER -